UBA3: A Potential Drug Target and Biomarker for Cancer (G9039)

Target Name: UBA3

NCBI ID: G9039

UBA3

UBA3: A Potential Drug Target and Biomarker for Cancer

UBA3 (uridine diphosphate nucleotide dehydrogenase-3) is an enzyme located in the nucleosome, which is a complex of DNA and histone proteins that makes up the chromosomes in the nucleus of a cell. UBA3 plays a crucial role in the regulation of DNA replication and repair, as well as cell growth and division. Mutations in the UBA3 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

In addition to its role in cellular biology, UBA3 has also been identified as a potential drug target. The high degree of sequence identity between UBA3 and drugs that target various oncogenic signaling pathways, such as the PI3K/Akt signaling pathway, has led to the focus of research on using UBA3 as a biomarker or drug target in cancer treatment.

One of the main advantages of targeting UBA3 is its potential to inhibit the activity of oncogenic signaling pathways. The PI3K/Akt signaling pathway is a well-established source of cancer-promoting signals, and several drugs that target this pathway have been approved for use in various types of cancer. UBA3 has been shown to be a critical enzyme in the PI3K/Akt signaling pathway, and inhibition of its activity has been shown to result in a reduction in cancer cell proliferation.

Another potential mechanism by which UBA3 may be targeted in cancer treatment is its role in cell growth and division. UBA3 is involved in the regulation of DNA replication and repair, which are critical processes for cancer cell growth and division. Inhibition of UBA3 activity has been shown to result in a reduction in cancer cell growth and an increase in cell cycle arrest. This may lead to the inhibition of the development of cancer cells and a reduction in their overall survival.

In addition to its potential role in cancer treatment, UBA3 has also been identified as a potential biomarker for cancer. The UBA3 gene has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that UBA3 may be a useful biomarker for the diagnosis and monitoring of cancer.

In conclusion, UBA3 is an enzyme that plays a critical role in the regulation of DNA replication and repair, as well as cell growth and division. Its role in cancer biology has led to its focus as a potential drug target and biomarker. Further research is needed to fully understand the effects of UBA3 inhibition on cancer cell growth and the development of cancer.

Protein Name: Ubiquitin Like Modifier Activating Enzyme 3

Functions: Catalytic subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Down-regulates steroid receptor activity. Necessary for cell cycle progression

The "UBA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets